CD8A and neoplasm: Tremendous effort has been focused on profiling patient’s tumor; nevertheless, we demonstrated that mGC patients with high openness at specific genomic positions of their circulating CD8+ T-cell chromatin responds better to pembrolizumab with longer PFS.